A novel nanobody-based immunocytokine of a mutant interleukin-2 as a potential cancer therapeutic

Abstract The immunotherapeutic application of interleukin-2 (IL-2) in cancer treatment is limited by its off-target effects on different cell populations and insufficient activation of anti-tumor effector cells at the site of the tumor upon tolerated doses. Targeting IL-2 to the tumor microenvironme...

Celý popis

Podrobná bibliografie

Hlavní autoři:	Arezoo Beig Parikhani, Rada Dehghan, Yeganeh Talebkhan, Elham Bayat, Alireza Biglari, Mohammad Ali Shokrgozar, Reza Ahangari Cohan, Esmat Mirabzadeh, Soheila Ajdary, Mahdi Behdani
Médium:	Artigo
Jazyk:	Inglês
Vydáno:	SpringerOpen 2024-02-01
Edice:	AMB Express
Témata:	Immunotherapy Immunocytokine Mutant IL-2 VEGFR2 Nanobody
On-line přístup:	https://doi.org/10.1186/s13568-023-01648-2
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!